We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TEM:NASDAQTempus AI, Inc. Analysis

Data as of 2026-07-30 - not real-time

$41.55

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Tempus AI, Inc. is trading just above its recent support of $40.77, with the current price of $41.55 reflecting a modest upside of roughly 2% from that floor. Technicals are mixed: the 20‑day SMA sits above the 50‑day SMA, yet the 200‑day SMA remains well above price, and a bearish MACD histogram (‑1.70) together with an RSI of 31.6 suggests the stock is oversold and vulnerable to further downside. Volatility is extreme at 69% over the past 30 days and beta exceeds 2.4, indicating high sensitivity to market swings. On the fundamentals side, revenue grew 36% YoY to $1.36 B, but margins are negative (operating margin ‑24%, profit margin ‑22%) and the balance sheet is strained with a debt‑to‑equity ratio over 300%, leading to a forward PE of ‑525 and a price‑to‑book of 17.9.
The recent definitive agreement to acquire Personalis expands TEM’s MRD capabilities, potentially unlocking higher‑margin data services, while institutional backing from BlackRock (5.1%) and ARK (5.5%) underscores confidence in the AI‑driven growth narrative. Analyst consensus remains a “Buy” with a median target near $64.5, implying a 55% upside, but the combination of high leverage, negative cash flow and extreme market sentiment (Fear‑Greed Index at “Extreme Greed”) warrants caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering just above technical support
  • Bearish MACD and oversold RSI
  • High short‑term volatility and beta

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Acquisition of Personalis expanding high‑margin services
  • Strong institutional ownership and analyst buy consensus
  • Revenue growth outpacing peers despite current losses

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic AI and data platform positioning in precision medicine
  • Potential for improved profitability as data services scale
  • Long‑term upside from market‑wide AI adoption in healthcare

Key Metrics & Analysis

Financial Health

Revenue Growth36.10%
Profit Margin-22.20%
P/E Ratio-524.8
ROE-81.58%
ROA-9.07%
Debt/Equity316.65
P/B Ratio17.9
Op. Cash Flow$-185743008
Free Cash Flow$-55760000
Industry P/E29.9

Technical Analysis

TrendNeutral
RSI31.6
Support$40.77
Resistance$63.11
MA 20$52.90
MA 50$51.05
MA 200$59.91
MACDBearish
VolumeIncreasing
Fear & Greed Index87.09

Valuation

Target Price$66.57
Upside/Downside60.22%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.47
Volatility69.30%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.